2023 annual financial data
CRISPR Therapeutics 2023 Operating margin
CRISPR Therapeutics 2023 operating margin with verified reported values.
Direct answer
Operating margin was -60.15%.
Operating income was -222,538,000 USD and net income was -153,610,000 USD.
Operating cash flow was -260,375,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 370,000,000 USD
- Operating income
- -222,538,000 USD
- Net income
- -153,610,000 USD
- Operating cash flow
- -260,375,000 USD